ReviewESMO gastrointestinal oncology2026
Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases.Clinical & experimental metastasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating tumor DNA (ctDNA) kinetics have emerged as a promising biomarker for monitoring treatment response in metastatic colorectal cancer (mCRC). We carried out a systematic review and meta-analysis to comprehensively assess the prognostic value of ctDNA kinetics during palliative systemic therapy, aiming to consolidate the current evidence and clarify its potential role in clinical practice. Materials and methods: PubMed, Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials were searched (last search 12 September 2025). Eligible studies assessed the association between ctDNA kinetics and outcomes in patients with mCRC receiving systemic palliative treatment. Meta-analyses were carried out to evaluate associations with survival outcomes. Results: A total of 64 studies, including data from >2760 patients with mCRC receiving palliative systemic therapy, met the eligibility criteria. Across studies, unfavorable ctDNA kinetics were consistently associated with poorer outcomes, including shorter overall survival (OS) [pooled hazard ratio (HR) 2.6, 95% confidence interval (CI) 2.2-3.2, Conclusion: ctDNA kinetics during palliative systemic therapy have strong prognostic value in mCRC. However, clinical implementation is hampered by methodological heterogeneity, particularly the use of study-specific ctDNA markers and non-validated cut-offs. Standardized and externally validated approaches are needed to support clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.